Clinical application of pharmacogenetics

被引：399

作者：

Spear, BB ^{[1
]}

Heath-Chiozzi, M ^{[1
]}

Huff, J ^{[1
]}

机构：

[1] Abbott Labs, N Chicago, IL 60064 USA

来源：

TRENDS IN MOLECULAR MEDICINE | 2001年 / 7卷 / 05期

关键词：

D O I：

10.1016/S1471-4914(01)01986-4

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Pharmacogenetics encompasses the involvement of genes in an individual's response to drugs. As such, the field covers a vast area including basic drug discovery research, the genetic basis of pharmacokinetics and pharmacodynamics, new drug development, patient genetic testing and clinical patient management. Ultimately, the goal of pharmacogenetics is to predict a patient's genetic response to a specific drug as a means of delivering the best possible medical treatment. By predicting the drug response of an individual, it will be possible to increase the success of therapies and reduce the incidence of adverse side effects.

引用

收藏

页码：201 / 204

页数：4

相关论文

共 19 条

[1] Comparison of three different sensitive assays for hepatitis B virus DNA in monitoring of responses to antiviral therapy [J].

Chan, HLY ;

Leung, NWY ;

Lau, TCM ;

Wong, ML ;

Sung, JJY .

JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (09) :3205-3208

[2] Adverse drug events in hospitalized patients - Excess length of stay, extra costs, and attributable mortality [J].

Classen, DC ;

Pestotnik, SL ;

Evans, RS ;

Lloyd, JF ;

Burke, JP .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (04) :301-306

[3] Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment [J].

Drazen, JM ;

Yandava, CN ;

Dubé, L ;

Szczerback, N ;

Hippensteel, R ;

Pillari, A ;

Israel, E ;

Schork, N ;

Silverman, ES ;

Katz, DA ;

Drajesk, J .

NATURE GENETICS, 1999, 22 (02) :168-170

[4] Pharmacogenomics: Translating functional genomics into rational therapeutics [J].

Evans, WE ;

Relling, MV .

SCIENCE, 1999, 286 (5439) :487-491

[5] Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy [J].

Furuya, H ;

FernandezSalguero, P ;

Gregory, W ;

Taber, H ;

Steward, A ;

Gonzalez, FJ ;

Idle, JR .

PHARMACOGENETICS, 1995, 5 (06) :389-392

[6] The effect of polymorphisms of the β2-adrenergic receptor on the response to regular use of albuterol in asthma [J].

Israel, E ;

Drazen, JM ;

Liggett, SB ;

Boushey, HA ;

Cherniack, RM ;

Chinchilli, VM ;

Cooper, DM ;

Fahy, JV ;

Fish, JE ;

Ford, JG ;

Kraft, M ;

Kunselman, S ;

Lazarus, SC ;

Lemanske, RF ;

Martin, RJ ;

McLean, DE ;

Peters, SP ;

Silverman, EK ;

Sorkness, CA ;

Szefler, SJ ;

Weiss, ST ;

Yandava, CN .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 162 (01) :75-80

[7] Genetic polymorphism of thiopurine S-methyltransferase: Clinical importance and molecular mechanisms [J].

Krynetski, EY ;

Tai, HL ;

Yates, CR ;

Fessing, MY ;

Loennechen, T ;

Schuetz, JD ;

Relling, MV ;

Evans, WE .

PHARMACOGENETICS, 1996, 6 (04) :279-290

[8] Clinical, genetic, and pharmacogenetic applications of the invader assay [J].

Kwiatkowski, RW ;

Lyamichev, V ;

de Arruda, M ;

Neri, B .

MOLECULAR DIAGNOSIS, 1999, 4 (04) :353-364

[9] Incidence of adverse drug reactions in hospitalized patients - A meta-analysis of prospective studies [J].

Lazarou, J ;

Pomeranz, BH ;

Corey, PN .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (15) :1200-1205

[10] PHARMACOGENETICS OF ACUTE AZATHIOPRINE TOXICITY - RELATIONSHIP TO THIOPURINE METHYLTRANSFERASE GENETIC-POLYMORPHISM [J].

LENNARD, L ;

VANLOON, JA ;

WEINSHILBOUM, RM .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 46 (02) :149-154